Juno Therapeutics Reports Fourth Quarter and 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Juno Therapeutics (JUNO) Misses Q4 EPS by 4c
March 1, 2017 4:20 PM ESTJuno Therapeutics (NASDAQ: JUNO) reported Q4 EPS of ($0.65), $0.04 worse than the analyst estimate of ($0.61). Revenue for the quarter came in at $21.2 million versus the consensus estimate of $14.56 million.
"2016 was a year of progress and learning for Juno and the cancer immunotherapy field. We continue to experience encouraging signs of clinical benefit in... More
